



RICHTER GEDEON

Change in the Nominations for the Board of Directors

Budapest, 24 April, 2026 – Gedeon Richter Plc. ("Richter") hereby announces that Mrs. Lászlóné Németh and Mr. Balázs Szepesi have decided not to pursue their nominations for membership of the Board of Directors.

This change related to the nominations does not affect the operation or the lawful conduct of the Board of Directors.

This disclosure is made in connection with the Richter's 2026 Annual General Meeting and provides information on a change concerning the nominations for membership of the Board of Directors.

About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

For further information:

Investors: Róbert Réthy, CFA
Media: Zsuzsa Beke

+36 20 342 2555
+36 20 916 4507

Richter Gedeon Vegyészeti Gyár Nyilvánosan Működő Rt.

Székhely: 1103 Budapest, Gyömrői út 19-21. • Levelezési cím: 1475 Budapest 10., Pf. 27. • Telefon: +36 1 431 4000
Fővárosi Törvényszék Cégbírósága Cg. 01-10-040944 • EU közösségi adószám: HU 10484878 • K&H Bank 10200971-20103088-00000000 • www.gedeonrichter.com